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Electrophoretic (A) and Southern blot (B) analysis of RT-PCR
products from AIDS-KS and normal skin tissues.
Lanes 1-5 and 10=AIDS-KS lesions, lanes 6-9=normal skin
Samples for lanes 5, 6, 9, and 10 obtained from the same AIDS-KS
patient. M=X174 RF DNA/Haelll fragments
(5’-GAGGAGCACCCCGTGCTGCTGA-3’ and 5’-CTAGAAGCA-
TTTGCGGTGGACGATGGAGGGGCC-3’)’ and FGF6 (5’-CTCTAC-
TGCAACGTGGGC-3’ and 5’-TGACTCGTAGGCATTGTA-3’)8 in a
PCR was done in buffer containing 10 mmol/I tris-HCI (pH 83), 50
mmol/I KCI, 1-5 mmol/I MgCl,, 10 I1g gelatin, 2 5 units of 7/Q
polymerase and 200 I1mol of each dNTP Samples were subjected to 35
cycles of denaturation (94’C, 1 mm), annealing (55’C, 1 mm) and
extension (72’C, 1 min).
Southern blot hybridisation was with both 32PATP end-labelled
probes for 0-actin (5’-GAAATCGTGCGTGACATTAAGGAGAAG-3’)
and for FGF6 (5’-TTGGAAGCTGGGCGTTGCGTACAATCT-3’).
Autoradiogram was obtained after exposure of Kodak X-ray film at
- 70&deg;C
Primer pairs from separate exons were used to inhibit amplification of
any contaminating genomic DNA sequences.
Six AIDS-associated KS tumour tissues and two normal
appearing skin specimens taken from sites distant from KS lesions
of these patients were studied. Two specimens of normal skin,
obtained from patients undergoing plastic surgery, served as HIV-1 1
negative controls. RNA was extracted after specimens had been
minced and ground. 1 Ilg RNA was treated with RNAse-free
DNAse 1 (Promega, Wisconsin). After heat inactivation cDNA was
made by using 200 units of Moloney murine leukaemia virus
reverse transcriptase (BRL, Maryland), 200 ng random hexamer,
225 umol of each dNTP, 50 mmol/1 "tris" HCI (pH 8-3), 75 mmol/1
KCI,10 mmoljl dithiothreitol, 3 mmol MgC 1,, 2 ltg nuclease-free
bovine serum albumin at 37&deg;C for 2 h. PCR was then performed by
co-amplification using both primer pairs for p-actin (see figure
legend). PCR products were analysed by gel electrophoresis and
Southern blot hybridisation. As shown in the figure all the samples
contained p-actin fragments (834 bp), showing that RNA had been
amplified. An amplified fragment of 258 bp was found in one
AIDS-KS sample. With the FGF6-specific probe and high
stringency washes, a distinct band was clearly detectable on
Southern blot hybridisation, which confirmed that FGF6 was
strongly expressed in this sample. Weak expression of FGF6 was
found in one other AIDS-KS specimen. There was no expression
of FGF6 in the four other fresh AIDS-KS specimens or in any of
the normal skin samples. The specimen with high expression of
FGF6 had been obtained from a lesion on the tongue and
histopathologically was a typical KS nodule with fascicles of spindle
cells arranged in a herringbone pattern. The KS specimen with
weak expression of FGF6 was from a biopsy-confirmed skin lesion
in a patient with disseminated disease.
The FGF family includes oncogene-encoding growth factors
which appear to have a similar broad mitogenic spectrum. They
promote the proliferation in culture of a variety of cells of
mesodermal and neuroectodermal origin and appear to have
angiogenic properties too.9 A role for one or more FGFs in the
pathophysiology of KS has been suggested.5 Histologically, KS
represents a complex tumour composed of fasicles of spindle-shaped
cells surrounding irregular shaped endothelial-lined vascular slits,
extravasated red blood cells and a mononuclear cell inflammatory
infiltrate. The FGF6 gene was identified by screening a cDNA
library with probes to the HST/K-FGF gene.8 The FGF6 protein is
therefore closely related to HST/K-FGF. FGF6 seems to possess
intrinsic oncogenic potential since it can transform cultured
fibroblasts.10 The finding that FGF6 is expressed in some fresh KS
tumour tissue may be an important clue to a possible role for FGF6
in oncogenesis and/or angiogenesis in KS.
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Acute transverse myelitis after tetanus
toxoid vaccination
SIR,-A case of optic neuritis and myelitis following a booster
dose of tetanus toxoid was reported by Dr Topaloglu and colleagues
(Jan 18, p 178). We recently managed a patient with acute transverse
myelitis that also followed tetanus toxoid booster administration.
A 50-year-old man with a penetrating wound to the foot was
given tetanus toxoid and immunoglobulin, single intravenous doses
of benzylpenicillin and flucloxacillin, and a course of oral
flucloxacillin. 6 days later he returned with a widespread
erythematous, maculopapular eruption, which was attributed to
flucloxacillin and which resolved on cessation of the drug. 10 days
later he again returned complaining of generalised myalgia,
lethargy, fatigue, and mild bifrontal headache. A viral illness was
diagnosed and symptomatic treatment advised.
12 days after his initial presentation he was admitted after the
onset, over several hours, of flaccid, areflexic paralysis of the legs,
associated with sensory loss to T6, moderately severe midthoracic
back pain, and urinary retention requiring an indwelling catheter.
His temperature was 38’6&deg;C but no focus of infection was evident.
Cerebrospinal fluid (CSF) examination revealed neutrophil
pleocytosis (white cells 1680 x 10/1, 90% polymorphs; red cells
885 x 106/1), raised protein (3900 mg/1), and a low glucose (1-6
mmol/1). Gram stain, bacterial antigen tests for Streptococcus
1112
pneumoniae, Haemophilus influenzae, and Neisseria meningitidis,
Ziehl-Neelsen stain, and india-ink stain were all negative.
Peripheral blood leucocytosis (18-4 x 109/1, 80% polymorphs) was
also noted. A myelogram imaged by computed tomography was
normal. Acute transverse myelitis was diagnosed and treatment was
started with intravenous dexamethasone 4 mg every 4 h and
ceftriaxone 1 g daily (empirically in view of the fever and
neutrophilia).
On the second hospital day a magnetic resonance imaging (MRI)
scan revealed areas of increased signal intensity on Tz-weighted
images at C7-T2 and T6-T7 vertebral levels. An MRI brain scan
was normal. He subsequently received intravenous pulsed
methylprednisolone 1 g daily for 5 days followed by oral
prednisolone 100 mg daily (tapering over 2 weeks to zero). Repeat
CSF examination on the fourth hospital day revealed white cells
65 x 106/1 (75% mononuclear), red cells 40 x 106/1, protein 7200
mg/1, and glucose 5 mmol/1. CSF cultures for bacteria, fungi, and
viruses were negative. Oligoclonal bands were not detected.
Serology for syphilis, Epstein-Barr virus, herpex simplex virus type
2, and HIV was negative; positive IgG results for measles,
varicella-zoster virus, and herpes simplex virus type 1 confirmed
past contact. An autoantibody screen, anticardiolipin antibody titre,
and serum vitamin B1z level were normal. After a month his
neurological deficits remained unchanged and he was transferred to
a rehabilitation unit.
Transverse myelitis has been reported after vaccination for
smallpox, rabies, rubella, cholera, and typhoid and poliomyelitis,
and for triple antigen1 and diphtheria, tetanus, and poliomyeliti S,2
but Topaloglu et al were the first to report myelitis after tetanus
toxoid vaccination alone. Reported neurological sequelae of tetanus
toxoid include brachial plexus neuropathy,3 polyradiculoneuritis,4 4
and relapsing demyelinating polyneuropathy.4 Although it is
possible that the myelopathy in our patient occurred independently
of vaccination, the timing and absence of an alternative explanation
may implicate tetanus toxoid.
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Stroke
SIR,-In your recent Stroke Octet series, the use of
anticoagulants after cardioembolic stroke was discussed. Dr Hart
(March 7, p 589) advises that intravenous heparin should probably
not be given until at least 48 h after stroke because the peak rise in
haemorrhagic transformation (HT) takes place before this time. Dr
Oppenheimer and Professor Hachinski (March 21, p 721) advise
waiting 4 days from stroke onset because most HTs will have taken
place by then. As these workers indicate, there is evidence that about
a quarter of HT occur late.
Two studies of haemorrhagic infarction in which sequential
computed tomographic (CT) scans were done and only low-dose
heparin or aspirin was usedl,2 have shown a high frequency of HT
after 3 days. Homig et all using sequential scans on days 3,7,14, and
21 after stroke found that 24 of 28 scans had HT after day 3 and the
peak incidence was between day 7 and 14. Half of Laureno and
co-workers’ sequentially scanned cases had HT after day 3.2 Okada
et all found that only 10 (15%) of 65 patients in whom HT
developed within a month of cerebral embolism showed
haemorrhage on the initial scan done 1-6 days after stroke.
Large cerebral infarcts are generally agreed to be a risk factor for
HT and HT increases the risk of haemorrhage into the infarct in
patients treated with conventional dose heparin.4 The Cerebral
Embolism Study Group4 showed that HT was commonly
associated with large infarcts, and less commonly with smaller
infarcts. The only study that has established statistically that a
specific size of infarct is associated with a low risk of HT is that of
Okada et al. These workers showed that infarcts of less than 10% of
the ipsilateral hemisphere area had a very low frequency of HT
(3%). Medium size infarcts had a high frequency of HT (50%),
similar to that of large infarcts (51 %).
The small size of an infarct on CT seems to be a better predictor
of a low frequency of future HT than does the absence of
haemorrhage on a 48 h or a 4 day scan. In deciding which patients to
treat with anticoagulants after embolic stroke, the main purpose of
an early CT scan should thus be to assess infarct size; the secondary
aim should be to exclude patients in whom HT has already
developed. Patients with infarcts larger than about 10% of the
ipsilateral hemisphere area should be given anticoagulants only with
caution because of the increased risk of future HT. A scan to assess
infarct size should probably be done about 48 h after stroke since
most infarcts are visible on CT by this time.
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SIR,-Dr Hart’s article (March 7, p 589) emphasising the
importance of atrial fibrillation (AF) in cardiogenic embolism to the
brain, affords the opportunity to address the regular absence of
mural thrombus from the left atrium and appendage, at necropsy
and on echocardiography, in non-valvular AF associated with
embolism. In 1953, I briefly reported that in such cases special
microscopic examination always disclosed a mural thrornbus.1 The
details were not included and this information has not become
generally known, although it forms the pathological rationale for
prophylactic anticoagulation.
This study involved the post-mortem examination of the left
atrial appendage in 20 cases of non-valvular AF associated with
systemic embolism, in which the left atrium and appendage showed
no grossly visible thrombus and no other source of an embolus.
Each appendage was divided longitudinally after which the two
halves were embedded in paraffin and sectioned serially at 8 pm,
and every 50th section was stained with haematoxylin and eosin.
Each appendage provided about 20 sections. In every case
organising mural thrombus was found in the appendage. Often it
was small and lay between the muscle trabeculae where it escaped
the eye of the prosector, even when the appendage was opened
longitudinally and examined with a loupe (figure). Likewise the
thrombus was usually too small to be detected on
echocardiography. Examination of two cases with AF but no
embolism also disclosed microscopic mural thrombus. As a control
measure the left atrial appendage was serially sectioned in 15 routine
post-mortem cases without AF, and mural thrombus was absent.
Longitudinal section of left atrial appendage showing small
mural thrombus (dark spot at top).
Haematoxylin and eosin stain ( x 1). ).
